García RMB, Pérez LMP, Rosete RA, González PM

Language: Spanish
References: 20
Page: 81-86
PDF size: 388.00 Kb.

ABSTRACT

Introduction. Influenza is a viral infection that affects the lower respiratory tract, having annual cycles. Oseltamivir has been one of the influenza antivirals on the World Health Organization (WHO) essential drugs list for a decade.
Objective. To determine the effectiveness and characteristics of adverse reactions in patients with influenza or influenza- like illness treated with oseltamivir.
Methods. Observational study with outpatient adult and adolescent patients under treatment with oseltamivir (75 mg every 12 hours), during the 2017-2018 winter season. Health status, functionality, quality of life, safety and satisfaction with medication were measured. The data were collected through booklets and telephone calls, delivered to the pharmacovigilance unit.
Results. 98 patients were included, 73.5% women, mean age 40 years. The median until improvement was fie days and for symptomatic relief it was seven days. The quality of life in the physical dimension improved on day seven. Global satisfaction with the treatment, average 84.1 and safety 94.4. 32 reported and resolved adverse reactions were detected, prevailing: nausea, dyspepsia, abdominal pain and dizziness.
Conclusion. Oseltamivir is effective as a treatment for influenza with a high level of satisfaction and presented some mild adverse reactions.

REFERENCES

1. Raus, K., Pleschka, S., Klein, P., Schoop, R. y Fisher, P., “Effect of an echinacea-based hot drink versus oseltamivir in influenza treatment: a randomized, double-blind, double-dummy, multicenter, noninferiority clinical trial”, Curr Ther Res Clin Exp, 2015, 77: 66-72.

2. oms, Centro de prensa, “Gripe (estacional)”, Organización Mundial de la Salud, Notas descriptivas, 10 de septiembre de 2019. Disponible en: https://www.who.int/es/ news-room/fact-sheets/detail/influenza-(seasonal)/.

3. Hsu, J., Santesso, N., Mustafa, R., Brozek, J., Chen, Y.L., Hopkins, J.P. et al., “Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies”, Ann Intern Med, 2012, 156 (7): 512-524.

4. Ruiz-Matus, C., Kuri-Morales, P. y Narro-Robles, J., “Comportamiento de las temporadas de influenza en México de 2010 a 2016, análisis y prospectiva”, Gac Med Mex, 2017, 153: 205-213.

5. Sinave, “Información relevante de influenza. Informe semanal de la temporada de influenza estacional 2018-2019/ Semana 20”, Sistema Nacional de Vigilancia Epidemiológica, Dirección General de Epidemiología, México, 2019.

6. who, The selection and use of essential medicines. Report of the 21th who Expert Committee on Selection and Use of Essential Medicines, 2017 (including the 20th who Model List of Essential Medicines and the 6th who Model List of Essential Medicines for Children), unedited version, Ginebra, World Health Organization, 2017.

7. Nicholson, E.G. y Muñoz, F.M., “A review of therapeutics in clinical development for respiratory syncytial virus and influenza in children”, Clin Ther, 2018, 40 (8): 1268-1281.

8. Jefferson, T., Jones, M.A., Doshi, P., Del Mar, C.B., Hama, R., Thompson, M.J., et al., “Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children”, Cochrane Database Syst Rev, 2014, 4: Cd008965.

9. Bardsley-Elliot, A. y Noble, S., “Oseltamivir”, Drugs, 1999, 58 (5): 851-860; discussion: 61-62.

10. Rafalsky, V., Averyanov, A., Bart, B., Minina, E., Putilovskiy, M., Andrianova, E. et al., “Efficacy and safety of ergoferon versus oseltamivir in adult outpatients with seasonal influenza virus infection: a multicenter, openlabel, randomized trial”, Int J Infect Dis, 2016, 51: 47-55.

11. Davidson, S., “Treating influenza infection, from now and into the future”, Front Immunol, 2018, 9: 1946.

12. who, Executive summary. The Selection and Use of Essential Medicines 2019. Report of the 22nd who Expert Committee on the Selection and Use of Essential Medicines, 1-5 April 2019, Ginebra, World Health Organization, 2019. Licence: cc by-nc-sa 3.0 igo.

13. who, World Health Organization Model List of Essential Medicines, 21th List, 2019, Ginebra, World Health Organization, 2019. Licence: cc by-nc-sa 3.0 igo.

14. Barrett, B., Brown, R.L., Mundt, M.P., Thomas, G.R., Barlow, S.K., Highstrom, A.D. et al., “Validation of a short form Wisconsin Upper Respiratory Symptom Survey (wurss-21)”, Health Qual Life Outcomes, 2009, 7: 76.

15. Atkinson, M.J., Sinha, A., Hass, S.L., Colman, S.S., Kumar, R.N., Brod, M. et al., “Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (tsqm), using a national panel study of chronic disease”, Health Qual Life Outcomes, 2004, 2: 12.

16. Gandek, B., Ware, J.E., Aaronson, N.K., Apolone, G., Bjorner, J.B., Brazier, J.E. et al., “Cross-validation of item selection and scoring for the sf-12 health survey in nine countries: results from the iqola Project. International Quality of Life Assessment”, J Clin Epidemiol, 1998, 51 (11): 1171-1178.

17. Muñoz-Cortés, G., García-Zavala, G.U. y Estrada-Andrade, M.E., “Enfermedad tipo influenza. Experiencia terapéutica en medicina familiar”, Rev Med Inst Mex Seguro Soc, 2013, 51 (4): 444-449.

18. Deshpande, P.R., Rajan, S., Sudeepthi, B.L.y Abdul Nazir, C.P., “Patient-reported outcomes: a new era in clinical research”, Perspect Clin Res, 2011, 2 (4): 137-144.

19. Regnault, A., Balp, M.M., Kulich, K. y Viala-Danten, M., “Validation of the Treatment Satisfaction Questionnaire for Medication in patients with cystic fibrosis”, J Cyst Fibros, 2012, 11 (6): 494-501.

20. Jones, M., Tett, S.E. y Del Mar, C., “Psychiatric adverse events in oseltamivir prophylaxis trials: novel comparative analysis using data obtained from clinical study reports”, Pharmacoepidemiol Drug Saf, 2018, 27 (11): 1217-1222.